As a central pillar of the global healthcare landscape in 2026, India's life sciences ecosystem has successfully transitioned from being the "pharmacy of the world" to a premier hub for high-value biopharmaceutical innovation.
The nation's formidable pharmaceutical sector now commands a significant share of the global market, driven by a massive production capacity for affordable generics and life-saving vaccine manufacturing. Under the transformative Biopharma SHAKTI initiative, India is rapidly scaling its expertise in biologics and biosimilars, supported by a robust network of over 1,000 accredited clinical trial sites.
The medical device industry is similarly evolving, leveraging the Production Linked Incentive (PLI) scheme to foster domestic R&D in advanced diagnostic imaging and implantable technologies.
Furthermore, the biotechnology sector is experiencing a surge in AI-driven drug discovery and genomics research, fueled by a vibrant startup culture and world-class academic institutions like the NIPERs.
With a strategic focus on digital health and a streamlined CDSCO regulatory framework, India offers a sophisticated CRDMO infrastructure that caters to the world's most complex therapeutic needs.
This integrated approach ensures that the country remains a competitive destination for foreign direct investment and a leader in pioneering healthcare innovation.
Policy initiatives are targeting modern research infrastructure: the MedTech Mitra program was launched to support innovators with clinical evaluation, regulatory navigation and adoption of medical technologies. The same year, national consultations advanced plans to apply CRISPR-based therapies for sickle cell disease, including protocols for clinical trials and readiness of GMP laboratories.
India has steadily expanded its science and innovation base, rising from 81st place in the Global Innovation Index in 2015 to 40th in 2024. This improvement reflects a decade of reforms and growing state support for R&D. To strengthen efficiency and accountability, the government launched a National R&D Dashboard to monitor investments and improve coordination across agencies. In addition, new programs such as the Vigyan Dhara scheme and the BioE3 Policy (Biotechnology for Economy, Environment and Employment) are designed to strengthen scientific research, biomanufacturing and sustainable practices.
India continues to draw strong private equity and venture capital interest, even as global funding slows. In the first half of 2025, PE/VC investments reached $26.4 billion, a 19% drop from the same period in 2024, but still 11% higher than the second half of last year. Deal activity remained steady at 593 transactions, with start-ups leading the way. They secured $6.8 billion across 366 deals, marking a 41% rise in value from the previous year. Growth-stage companies added another $6.5 billion through 113 deals. Healthcare stood out with some of the biggest transactions. KKR invested $400 million in HealthCare Global Enterprises (HCG), one of India's top cancer care providers, and extended $600 million in credit financing to Manipal Education and Medical Group. These deals signal that investors continue to see India's healthcare and life sciences sector as a growth opportunity. Exits also picked up pace, totaling $11.6 billion across 99 deals in the first half of 2025. IPO exits were particularly strong, more than doubling in value year-on-year to $1.5 billion across eight listings.
India's life sciences and pharmaceutical sector combines large, globally competitive domestic companies, such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Biocon, Divi's Laboratories and Syngene International, with a strong base in generics, APIs, biosimilars, vaccines and contract research and manufacturing. At the same time, multinational corporations including Thermo Fisher Scientific, Roche Pharma India, Novartis, Pfizer India and Merck KGaA are expanding manufacturing, R&D, diagnostics and clinical trial activities, reinforcing India's role as a global hub across the life sciences value chain.
Global medical device multinationals, including Medtronic, Siemens Healthineers, Philips and GE HealthCare, are expanding their footprint in India through new R&D centers and manufacturing facilities, highlighted by Medtronic's $350 million investment in Hyderabad. At the same time, domestic companies such as Trivitron Healthcare, Poly Medicure and Meril Life Sciences are scaling up capabilities in areas including cardiovascular stents and diagnostic equipment, strengthening India's home-based medtech ecosystem.
Rapid growth in clinical research activity has positioned India as the world's third-largest hub for clinical trials by 2024, reflecting an estimated CAGR of about 80% since 2019. In 2024 alone, roughly 18,000 new clinical trials were registered in the country, representing a year-over-year increase of approximately 50%.
New Delhi, Delhi, India
Within the life sciences sector, India accounted for 20% of global generics exports by volume and supplied more than 60% of the world's vaccines as of 2023. The country ranks third worldwide for pharmaceutical production by volume and 14th by value. By 2025, life sciences global capability centers (GCCs) employed more than 150,000 professionals, highlighting the sector's increasing role in global R&D, digital health and analytics. The Indian bioeconomy has expanded from $10 billion in 2014 to more than $130 billion in 2024, and is expected to surpass $300 billion by 2030.
India has the world's largest youth population, forming a skilled workforce across R&D, production, engineering and healthcare professions. This talent pool is one of the strongest drivers attracting multinational organizations to expand operations in India, providing companies with ready access to scientific and technical expertise.
India's real estate and infrastructure sectors are increasingly geared toward life sciences, building specialized spaces such as R&D labs, manufacturing facilities, bio-clusters, cold chain logistics and secure storage. Trends like integrated townships, special economic zones (SEZs), knowledge cities and bio-incubators are creating dedicated environments for startups and established firms alike. This infrastructure expansion strengthens India's position as a hub for both domestic innovation and global partnerships.
India has developed into a leading hub for specialized life sciences talent. By 2025, about half of all pharma and biotech innovation-focused global capability centers were located in the country, spanning clinical development, digital health and regulatory services. India continues to offer a cost advantage, with R&D expenses estimated to be 30% to 35% lower than in developed markets. The innovation ecosystem is expanding rapidly: as of 2023, the country was home to more than 6,000 biotech startups, with government projections targeting 10,000 by 2025. Public agencies such as BIRAC have supported more than 5,000 startups and SMEs through funding and incubation, sustaining this pipeline of emerging companies.
Claim Profile to Update Website
Claim Profile to Update Contact Information
Claim Your Profile to Add Related Links
Claim Your Profile to add downloadable documentation
https://pharmaville.com/wp-content/uploads/2026/02/Pharmaville-India-references.pdf
